GLP-1 receptor agonists have become increasingly popular, and its easy to see why
Clinical Evidence Base and Regulatory Status BPC-157 has never been approved by the FDA for any human use
GLP-1s and Obesity Coverage: Differing Perspectives for Employers and Health Plans Posted on August 21, 2025 A Snippet From Our GLP-1 Spotlight Webinar Key Points Employers tend to view obesity as a chronic condition, while health plans lean slightly toward viewing obesity as a lifestyle condition
Its primary effects occur in the central nervous system , where activation of these receptors enhances dopamine signaling in key areas such as the nucleus accumbens and medial preoptic region
Choose lower-calorie options like a spirit with soda water, dry wine, or light beer over sugary cocktails
While some healthcare providers continue to prescribe compounded peptides, the FDA peptide warning maintains that patients should be aware of the uncertainties surrounding these products and the potential risks associated with their use